Company intelligence / Profile preview

Arctos Medical

Ownership: Private
Development stage: Other

Overview

Arctos Medical developed a preclinical-stage, adeno-associated virus-based gene therapy that delivers proprietary light-sensitive genes (“optogenes”) to specific retinal cells. This approach aims to convert these targeted cells into replacement photoreceptors, potentially restoring sight in patients with inherited or acquired blindness due to photoreceptor loss. Unlike traditional gene therapies that correct single-gene defects, this technology could address multiple forms of IRD regardless of the causative mutation. No clinical results have been reported as the program was preclinical at acquisition.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyOptogenetics-based therapy
Industry: Biotech

Partnerships

+ND CapitalNovartis Venture Fund

Beyond the preview

Go deeper on Arctos Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arctos Medical.

Explore the full profile